Skip to main content
Premium Trial:

Request an Annual Quote

Medvet to Distribute Agendia's MammaPrint Test in Australia

NEW YORK (GenomeWeb News) - Medvet Science will distribute Agendia’s MammaPrint breast cancer prognosis test to hospitals in Australia, Agendia said today.
 
The Dutch company said its microarray-based test was developed from a 70-gene tumor expression profile that predicts disease outcome, and will be used by physicians to help plan follow-up therapy. 
 
Agendia CEO Bernhard Sixt said the Australia agreement is part of the company’s planned global expansion for the test. Medvet also has agreements in place with companies to market the test in South America, the UK, and South Africa. 
 
The test may “reduce consequences and associated costs of post-operative treatment,” said Greg Johansen, general manager of Adelaide-based Medvet.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.